Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type2 diabetes: A meta-analysis

Diabetic Medicine

Volumn 28, Issue 10, 2011, Pages 1182-1187

  Blacklock, C L ^a   Hirst, J A ^a   Taylor, K S ^a   Stevens, R J ^a   Roberts, N W ^a   Farmer, A J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Dose; Microalbuminuria; Type 2 diabetes

Indexed keywords

ALBUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; TELMISARTAN; VALSARTAN;

ARTICLE; CARDIOVASCULAR RISK; COCHRANE LIBRARY; DISEASE COURSE; DOSE RESPONSE; EMBASE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EVIDENCE-BASED MEDICINE; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 80053009300     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03341.x     Document Type: Article

References (15)

1. National Collaborating Centre for Chronic Conditions. Type2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (update). 2008. London: Royal College of Physicians. Available at Last accessed 27 September 2010.
2. Gimeno-Orna JA, Molinero-Herguedas E, Sanchez-Vano R, Lou-Arnal LM, Boned Juliani B, Castro-Alonso FJ. Microalbuminuria presents the same vascular risk as overt CVD in type2 diabetes. Diabetes Res Clin Pract 2006; 74: 103-109.
3. Yuyun MF, Dinneen SF, Edwards OM, Wood E, Wareham NJ. Absolute level and rate of change of albuminuria over 1year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med 2003; 20: 277-282.
4. De Zeeuw D, Remuzzi G, Parving H, Keane WF, Zhang Z, Shahinfar S et al. Proteinuria, a target for renoprotection in patients with type2 diabetic nephropathy; lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
5. Basi S, Fesler P, Mimran A, Lewis J. Microalbuminuria in type2 diabetes and hypertension: a marker, treatment target, or innocent bystander? Diabetes Care 2008; 31: S194-201.
6. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
7. Strippoli GFM, Bonifati C, Craig ME, Navaneethan SD, Craig JC. Angiotensin-converting enzyme inhibitors and angiotensinII receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; 4: CD006257.
8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
9. Hollenberg N, Parving H, Viberti G, Remuzzi G, Ritter S, Zelenkofske S et al. Albuminuria response to very high-dose valsartan in type2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926.
10. Muirhead N, Feagan B, Mahon J, Lewanczuk R, Rodger NW, Botteri F et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999; 60: 650-660.
11. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type2 diabetes: a post-hoc analysis of the incipient to overt: AngiotensinII blocker, telmisartan, investigation on type2 diabetic nephropathy (INNOVATION) study. Hypertens Res 2008; 31: 657-664.
12. Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type2 diabetes. N Engl J Med 2001; 345: 870-878.
13. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
14. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-1183.
15. Marre M, Lievre M, Chatellier G, Mann JFE, Passa P, Menard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Br Med J 2004; 328: 495.